A Budget-Impact (BI) Analysis of Tazemetostat for the Treatment of 3L+Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States

被引：0
|
作者：
Watson, Lucy [1 ]
Harrison, Owen [1 ]
Cockrum, Paul [2 ]
Veazey, Kylee [2 ]
Gaugris, Sabine [1 ]
Kim, George [3 ]
机构：
[1] FIECON, St Albans, England
[2] Ipsen, Cambridge, MA USA
[3] Mayo Clin Florida, Div Hematol & Oncol, Jacksonville, FL USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
IBCL; tazemetostat; relapsed/refractory follicular lymphoma; R/R FL; budget impact; cost saving;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-461
引用
收藏
页码：S498 / S499
页数：2
相关论文
共 50 条
  • [41] Subcutaneous Epcoritamab With Rituximab plus Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial
    Falchi, Lorenzo
    Leppa, Sirpa
    Wahlin, Bjorn E.
    Nijland, Marcel
    Christensen, Jacob Haaber
    De Vos, Sven
    Holte, Harald
    Linton, Kim M.
    Abbas, Aqeel
    Wang, Liwei
    Dinh, Minh
    Elliott, Brian
    Belada, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S392 - S392
  • [42] ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)
    Fowler, Nathan
    Dreyling, Martin
    Dickinson, Michael
    Martinez-Lopez, Joaquin
    Kolstad, Arne
    Butler, Jason
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter
    Ho, P. Joy
    Antonio Perez-Simon, Jose
    Chen, Andy
    Nastoupil, Loretta
    von Tresckow, Bastian
    Ferreri, Andres Jose Maria
    Teshima, Takanori
    Patten, Piers
    McGuirk, Joseph
    Petzer, Andreas
    Offner, Fritz
    Viardot, Andreas
    Zinzani, Pier
    Malladi, Ram
    Paule, Ines
    Zia, Aiesha
    Awasthi, Rakesh
    Han, Xia
    Germano, Davide
    O'Donovan, Darragh
    Ramos, Roberto
    Masood, Aisha
    Thieblemont, Catherine
    Schuster, Stephen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S534 - S535
  • [43] Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of Third Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
    Nastoupil, Loretta J.
    Bonner, Ashley
    Wang, Pearl
    Almuallem, Lamees
    Desai, Jigar
    Fasan, Omotayo
    Farazi, Thalia
    Kumar, Jinender
    Dahiya, Saurabh
    BLOOD, 2023, 142
  • [44] BUDGET IMPACT OF ZANUBRUTINIB TO TREAT RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA FROM A PAYER PERSPECTIVE IN THE UNITED STATES
    Liu, S.
    Yang, K.
    Carter, J.
    Zimmerman, T.
    Tang, B.
    VALUE IN HEALTH, 2022, 25 (01) : S62 - S62
  • [45] Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L+relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results
    Oluwole, Olalekan O.
    Ray, Markqayne D.
    Davies, Neil
    Bradford, Rory
    Jones, Calum
    Patel, Anik R.
    Locke, Frederick L.
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 230 - 239
  • [46] Polatuzumab vedotin plus obinutuzumab plus venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.
    Bannerji, Rajat
    Yuen, Sam
    Phillips, Tycel Jovelle
    Arthur, Christopher
    Isufi, Iris
    Marlton, Paula
    Seymour, John Francis
    Corradini, Paolo
    Molinari, Annalia
    Gritti, Giuseppe
    Emmons, Robert
    Hirata, Jamie
    Musick, Lisa
    Saha, Sourish
    Croft, Brandon
    Flowers, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Primary Efficacy and Safety Analysis of a Global Phase II Study of Zandelisib Administered by Intermittent Dosing (ID) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): The TIDAL Study
    Phillips, Tycel
    Jurczak, Wojciech
    Ribrag, Vincent
    Linton, Kim
    Collin, Graham P.
    Lopez-Jimenez, Javier
    Reddy, Nishitha
    Mengarelli, Andrea
    Musuraca, Gerardo
    Sheehy, Oonagh
    Xu, Weiming
    Azoulay, Michel
    Ghalie, Richard G.
    Zinzani, Pier Luigi
    Zelenetz, Andrew D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S387 - S388
  • [48] Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial.
    Schuster, Stephen J.
    Dickinson, Michael J.
    Dreyling, Martin H.
    Martinez, Joaquin
    Kolstad, Arne
    Butler, Jason Paul
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio C.
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter A.
    Abdelhady, Ahmed M.
    Zia, Aiesha
    Morisse, Mony Chenda
    Fowler, Nathan Hale
    Thieblemont, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL.
    Zelenetz, Andrew David
    Jurczak, Wojciech
    Ribrag, Vincent
    Linton, Kim
    Collins, Graham P.
    Lopez-Jimenez, Javier
    Reddy, Nishitha
    Mengarelli, Andrea
    Phillips, Tycel Jovelle
    Musuraca, Gerardo
    Sheehy, Oonagh
    Li, Joanne
    Xu, Weiming
    Azoulay, Michel Meyer
    Ghalie, Richard
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] Cost-effectiveness of treating relapsed or refractory 3L+follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States
    Oluwole, Olalekan O.
    Ray, Markqayne D.
    Zur, Richard M.
    Ferrufino, Cheryl P.
    Doble, Brett
    Patel, Anik R.
    Bilir, S. Pinar
    FRONTIERS IN IMMUNOLOGY, 2024, 15
12345